Detailed Review of Tebentafusp (IMCgp100) in Metastatic Uveal Melanoma Published in Issue of Cancers
OXFORD, England & CONSHOHOCKEN, Pa. & ROCKVILLE, Md--(BUSINESS WIRE)--Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announce the publication of “Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma” in a special issue on uveal melanoma in Cancers, an international, peer-reviewed monthly journal.1 Written by Dr. Bertil Damato, Dr. Richard Carvajal and experts at Immunocore, the paper provides an overview of the biology of uveal melanom